Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Short term Debt (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Short term Debt for 5 consecutive years, with $2.1 billion as the latest value for Q3 2025.

  • Quarterly Short term Debt fell 64.02% to $2.1 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Sep 2025, down 64.02% year-over-year, with the annual reading at $2.1 billion for FY2025, 64.02% down from the prior year.
  • Short term Debt hit $2.1 billion in Q3 2025 for Universe Pharmaceuticals, down from $5.9 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.9 billion in Q3 2024 to a low of $19723.0 in Q3 2021.
  • Historically, Short term Debt has averaged $1.6 billion across 5 years, with a median of $5.5 million in 2023.
  • Biggest five-year swings in Short term Debt: skyrocketed 106726.27% in 2024 and later crashed 64.02% in 2025.
  • Year by year, Short term Debt stood at $19723.0 in 2021, then soared by 17033.62% to $3.4 million in 2022, then surged by 62.24% to $5.5 million in 2023, then surged by 106726.27% to $5.9 billion in 2024, then plummeted by 64.02% to $2.1 billion in 2025.
  • Business Quant data shows Short term Debt for UPC at $2.1 billion in Q3 2025, $5.9 billion in Q3 2024, and $5.5 million in Q3 2023.